Azithromycin Reduction to Reach Elimination of Trachoma

PHASE4CompletedINTERVENTIONAL
Enrollment

74,920

Participants

Timeline

Start Date

May 29, 2021

Primary Completion Date

December 18, 2024

Study Completion Date

December 18, 2024

Conditions
Trachoma
Interventions
DRUG

Azithromycin

In study communities randomized to the Azithromycin Continuation arm, all individuals aged 1 month and older will receive a single mass distribution of azithromycin several weeks after the baseline and 36-month monitoring visits. In study communities randomized to Azithromycin Discontinuation, participants will receive no treatment.

Trial Locations (1)

Unknown

Programme National de Santé Oculaire (PNSO), Niamey

All Listed Sponsors
collaborator

Programme National de Santé Oculaire (PNSO)

UNKNOWN

collaborator

National Eye Institute (NEI)

NIH

lead

University of California, San Francisco

OTHER